Leo Dahl

Leo Dahl

Auto-generated profile, based on publicly available information

Leo Dahl

Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAnders Mälarstig
Anders Mälarstig
FGFelix Grassmann
Felix Grassmann
LDLeo Dahl
Leo Dahl
MDMarios Dimitriou
Marios Dimitriou
DMDianna McLeod
Dianna McLeod
ÅHÅsa K. Hedman
Åsa K. Hedman
Biomarkers for early detection of breast cancer may complement population screening approaches to enable earlier and more precise treatment. The blood proteome is an important source for biomarker discovery but so far, few proteins have been identified with breast cancer risk. Here, we measure 2929 unique proteins in plasma from 598 women selected from the Karolinska Mammography Project to explore the association between protein levels, clinical characteristics, and gene variants, and to identify proteins with a causal role in breast cancer. We present 812 cis-acting protein quantitative trait loci for 737 proteins which are used as instruments in Mendelian randomisation analyses of breast cancer risk. Of those, we present five proteins (CD160, DNPH1, LAYN, LRRC37A2 and TLR1) that show a potential causal role in breast cancer risk with confirmatory results in independent cohorts. Our study suggests that these proteins should be further explored as biomarkers and potential drug targets in breast cancer.

2 April 2024 in Communications Medicine
Verified
Journal Article
Open access
PDF file
CFClaudia Fredolini
Claudia Fredolini
TDTea Dodig-Crnković
Tea Dodig-Crnković
ABAnnika Bendes
Annika Bendes
LDLeo Dahl
Leo Dahl
MDMatilda Dale
Matilda Dale
JSJochen Schwenk
Jochen Schwenk
Background: Self-sampling of dried blood spots (DBS) offers new routes to gather valuable health-related information from the general population. Yet, the utility of using deep proteome profiling from home-sampled DBS to obtain clinically relevant insights about SARS-CoV-2 infections remains largely unexplored.Methods: Our study involved 228 individuals from the general Swedish population who used a volumetric DBS sampling device and completed questionnaires at home during spring 2020 and summer 2021. Using multi-analyte COVID-19 serology, we stratified the donors by their response phenotypes, divided them into three study sets, and analyzed 276 proteins by proximity extension assays (PEA). After normalizing the data to account for variances in layman-collected samples, we investigated the association of DBS proteomes with serology and self-reported information.Results: Our three studies display highly consistent variance of protein levels and share associations of proteins with sex (e.g., MMP3) and age (e.g., GDF-15). Studying seropositive (IgG+) and seronegative (IgG-) donors from the first pandemic wave reveals a network of proteins reflecting immunity, inflammation, coagulation, and stress response. A comparison of the early-infection phase (IgM+IgG-) with the post-infection phase (IgM-IgG+) indicates several proteins from the respiratory system. In DBS from the later pandemic wave, we find that levels of a virus receptor on B-cells differ between seropositive (IgG+) and seronegative (IgG-) donors.Conclusions: Proteome analysis of volumetric self-sampled DBS facilitates precise analysis of clinically relevant proteins, including those secreted into the circulation or found on blood cells, augmenting previous COVID-19 reports with clinical blood collections. Our population surveys support the usefulness of DBS, underscoring the role of timing the sample collection to complement clinical and precision health monitoring initiatives.

5 May 2023 in Science Advances
Verified
Journal Article
Open access
LDLeo Dahl
Leo Dahl
IKIlana B. Kotliar
Ilana B. Kotliar
ABAnnika Bendes
Annika Bendes
TDTea Dodig-Crnković
Tea Dodig-Crnković
SFSamuel Fromm
Samuel Fromm
JSJochen Schwenk
Jochen Schwenk
G protein–coupled receptors (GPCRs) control critical cellular signaling pathways. Therapeutic agents including anti-GPCR antibodies (Abs) are being developed to modulate GPCR function. However, validating the selectivity of anti-GPCR Abs is challenging because of sequence similarities among individual receptors within GPCR subfamilies. To address this challenge, we developed a multiplexed immunoassay to test >400 anti-GPCR Abs from the Human Protein Atlas targeting a customized library of 215 expressed and solubilized GPCRs representing all GPCR subfamilies. We found that ~61% of Abs tested were selective for their intended target, ~11% bound off-target, and ~28% did not bind to any GPCR. Antigens of on-target Abs were, on average, significantly longer, more disordered, and less likely to be buried in the interior of the GPCR protein than the other Abs. These results provide important insights into the immunogenicity of GPCR epitopes and form a basis for designing therapeutic Abs and for detecting pathological auto-Abs against GPCRs.

22 December 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
FGFelix Grassmann
Felix Grassmann
AMAnders Mälarstig
Anders Mälarstig
LDLeo Dahl
Leo Dahl
ABAnnika Bendes
Annika Bendes
MDMatilda Dale
Matilda Dale
KCKamila Czene
Kamila Czene
Objective: Current breast cancer risk prediction scores and algorithms can potentially be further improved by including molecular markers. To this end, we studied the association of circulating plasma proteins using Proximity Extension Assay (PEA) with incident breast cancer risk. Subjects: In this study, we included 1577 women participating in the prospective KARMA mammographic screening cohort. Results: In a targeted panel of 164 proteins, we found 8 candidates nominally significantly associated with short-term breast cancer risk (P < 0.05). Similarly, in an exploratory panel consisting of 2204 proteins, 115 were found nominally significantly associated (P < 0.05). However, none of the identified protein levels remained significant after adjustment for multiple testing. This lack of statistically significant findings was not due to limited power, but attributable to the small effect sizes observed even for nominally significant proteins. Similarly, adding plasma protein levels to established risk factors did not improve breast cancer risk prediction accuracy. Conclusions: Our results indicate that the levels of the studied plasma proteins captured by the PEA method are unlikely to offer additional benefits for risk prediction of short-term overall breast cancer risk but could provide interesting insights into the biological basis of breast cancer in the future.

2 August 2024 in Science Advances
Verified
Journal Article
Open access
IKIlana B. Kotliar
Ilana B. Kotliar
ABAnnika Bendes
Annika Bendes
LDLeo Dahl
Leo Dahl
Yuanhuang ChenYuanhuang Chen
Yuanhuang Chen
MSMarcus Saarinen
Marcus Saarinen
TSThomas Sakmar
Thomas Sakmar
Receptor activity–modifying proteins (RAMPs) form complexes with G protein–coupled receptors (GPCRs) and may regulate their cellular trafficking and pharmacology. RAMP interactions have been identified for about 50 GPCRs, but only a few GPCR-RAMP complexes have been studied in detail. To elucidate a comprehensive GPCR-RAMP interactome, we created a library of 215 dual epitope-tagged (DuET) GPCRs representing all GPCR subfamilies and coexpressed each GPCR with each of the three RAMPs. Screening the GPCR-RAMP pairs with customized multiplexed suspension bead array (SBA) immunoassays, we identified 122 GPCRs that showed strong evidence for interaction with at least one RAMP. We screened for interactions in three cell lines and found 23 endogenously expressed GPCRs that formed complexes with RAMPs. Mapping the GPCR-RAMP interactome expands the current system-wide functional characterization of RAMP-interacting GPCRs to inform the design of selective therapeutics targeting GPCR-RAMP complexes.

21 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ABAnnika Bendes
Annika Bendes
SBSophia Björkander
Sophia Björkander
MKMaura M. Kere
Maura M. Kere
SMSimon Kebede Merid
Simon Kebede Merid
AKAshish Kumar
Ashish Kumar
JSJochen Schwenk
Jochen Schwenk
Population-based studies of circulating blood proteins have provided profound insights into human biology. However, short-lived changes often remained undetected. To address this, we performed a comprehensive longitudinal dried blood spot (DBS) self-sampling study in 808 young adults of the BAMSE cohort during 2020-2022. We profiled serological, autoimmune, and proteomic phenotypes in relation to SARS-CoV-2 exposures (infection, vaccination), physiological traits, genetic variation, and blood counts. Data-driven seroclustering revealed dynamic immune response to both exposures, while analysis of anti-interferon autoantibodies (AAbs) uncovered associations of pre-existing stable AAbs with prolonged COVID-19 symptoms. Genome-wide mapping determined 664 pQTLs, with cis-pQTLs associated showing increased longitudinal stability. We also identified relationships between blood cell counts and DBS proteins beyond the hematocrit effects. Paired pre- and post-exposure highlighted transient alterations for infection (e.g. LAP3) and vaccinations (e.g. TIMP3). Multi-molecular phenotyping in self-sampling can capture dynamic immune trajectories, informing precision medicine efforts with clinically valuable insights on short-term variability in health phenotypes.